Biomedical Engineering Reference
In-Depth Information
104. Koppu S, Oh YJ, Edrada-Ebel R, Blatchford DR, Tetley L, Tate RJ, Dufes C (2010) Tumor
regression after systemic administration of a novel tumor-targeted gene delivery system
carrying a therapeutic plasmid DNA. J Control Release 143:215-221
105. Curiel DT, Agarwal S, Romer N, Wagner E, Cotten M, Birnstiel ML, Boucher RC (1992)
Gene transfer to respiratory epithelial cells via the receptor-mediated endocytosis pathway.
Am J Resp Cell Mol Biol 6:247-252
106. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005) Sequence-specific
knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits
tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65:8984-8992
107. Heidel JD, Liu JY, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW, Davis ME (2007) Potent
siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro
and in vivo. Clin Cancer Res 13:2207-2215
108. Tietze N, Pelisek J, Philipp A, Roedl W, Merdan T, Tarcha P, Ogris M, Wagner E (2008)
Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded
siRNA polyplexes for downregulation of Ran. Oligonucleotides 18:161-174
109. Russ V, Frohlich T, Li Y, Halama A, Ogris M, Wagner E (2010) Improved in vivo gene
transfer into tumor tissue by stabilization of pseudodendritic oligoethylenimine-based
polyplexes. J Gene Med 12:180-193
110. Pun SH, Tack F, Bellocq NC, Cheng J, Grubbs BH, Jensen GS, Davis ME, Brewster M,
Janicot M, Janssens B, Floren W, Bakker A (2004) Targeted delivery of RNA-cleaving DNA
enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles.
Cancer Biol Ther 3:641-650
111. Xu B, Wiehle S, Roth JA, Cristiano RJ (1998) The contribution of poly-L-lysine, epidermal
growth factor and streptavidin to EGF/PLL/DNA polyplex formation. Gene Ther
5:1235-1243
112. Blessing T, Kursa M, Holzhauser R, Kircheis R, Wagner E (2001) Different strategies for
formation of pegylated EGF-conjugated PEI/DNA complexes for targeted gene delivery.
Bioconjug Chem 12:529-537
113. Wolschek MF, Thallinger C, Kursa M, Rossler V, Allen M, Lichtenberger C, Kircheis R,
Lucas T, Willheim M, Reinisch W, Gangl A, Wagner E, Jansen B (2002) Specific systemic
nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice.
Hepatology 36:1106-1114
114. de Bruin K, Ruthardt N, von Gersdorff K, Bausinger R, Wagner E, Ogris M, Brauchle C (2007)
Cellular dynamics of EGF receptor-targeted synthetic viruses. Mol Ther 15:1297-1305
115. Chen J, Gamou S, Takayanagi A, Shimizu N (1994) A novel gene delivery system using EGF
receptor-mediated endocytosis 97. FEBS Lett 338:167-169
116. Liu X, Tian P, Yu Y, Yao M, Cao X, Gu J (2002) Enhanced antitumor effect of EGF
R-targeted p21WAF-1 and GM-CSF gene transfer in the established murine hepatoma by
peritumoral injection. Cancer Gene Ther 9:100-108
117. Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J, Xu Y, Gu J (2005) Identification and characteriza-
tion of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of
therapeutics. Faseb J 19:1978-1985
118. Chiu SJ, Ueno NT, Lee RJ (2004) Tumor-targeted gene delivery via anti-HER2 antibody
(trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release 97:357-369
119. Germershaus O, Merdan T, Bakowsky U, Behe M, Kissel T (2006) Trastuzumab-polyethy-
lenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors. Bioconjug
Chem 17:1190-1199
120. Moffatt S, Papasakelariou C, Wiehle S, Cristiano R (2006) Successful in vivo tumor targeting
of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular
conjugate. Gene Ther 13:761-772
121. Wood KC, Azarin SM, Arap W, Pasqualini R, Langer R, Hammond PT (2008) Tumor-
targeted gene delivery using molecularly engineered hybrid polymers functionalized with a
tumor-homing peptide. Bioconjug Chem 19:403-405
